Previous close | 24.66 |
Open | 24.61 |
Bid | 25.09 x 200 |
Ask | 25.16 x 200 |
Day's range | 24.22 - 25.23 |
52-week range | 13.72 - 33.34 |
Volume | |
Avg. volume | 665,940 |
Market cap | 1.466B |
Beta (5Y monthly) | 2.05 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.39 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 44.20 |
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors. The Company also announced that Patrick Machado has stepped down as a member o
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Protagonist Therapeutics Inc (NASDAQ:PTGX), a biopharmaceutical company, has reported an insider sale according to a recent SEC filing.